Dublin, Jan. 20, 2016 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/q8ggs7/human_microbiome) has announced the addition of the "Human Microbiome Market by Indication, Application, Product, Product Research & Technology Research - Global Forecast to 2023" report to their offering.
Existing opportunities and huge research investments by several key players in microbiome arena facilitate human microbiome market to gain market traction
The human microbiome market is an emerging market with abundant opportunities. The market is expected to flourish within five to seven years owing to a number of products currently under the clinical trial phase. The market potential is quite large, considering the structure of the market.
The factors driving this market include rising aging population, increasing incidences of lifestyle diseases, gradual demand for efficient and safe medication with no side effects, and treatment of diseases having a limited success rate. The factors restraining this market include lack of comprehensive research to assist in market pull, lack of awareness among the population regarding the efficient usage and effect of prebiotics and probiotics, and impending government regulations on probiotics and prebiotics.
The human microbiome market is divided into three major segments, namely, application, disease, and product. Different products in the market and its usage are expected to contribute to the growth of the overall market. Increase in lifestyle diseases will help the market to proliferate, while the application segment is also considered as a major driving factor for the market. Also, the human microbiome research spending market is broadly segmented by product and technology.
Europe is expected to command as a resourceful market with the largest share in the human microbiome market and expected to grow within the coming years. The primary growth driver for Europe is the aging population size and the increasing lifestyle diseases. The increasing need among the population to stay fit and have a healthy lifestyle has leveraged the use of prebiotics and probiotics. The consumers seek for a wider variety of food and beverages that contain beneficial probiotics and prebiotics and other food supplements that helps to maintain microbiome balance.
APAC accounted for the second-largest market share and will be the main focus of the market in the coming five years that will register high-growth rates for all the segments. The U.S. market at present is a niche market due to the lack of awareness among the population regarding the beneficial usage of prebiotics and probiotics. However, the U.S. is expected to be a potential market for the growth of this region in the forecast period.
The key players in the human microbiome market are Enterome Bioscience (France), Yakult (Japan), DuPont (U.S.), Metabiomics Corporation (U.S.), and ViThera Pharmaceuticals (U.S.)
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Human Microbiome Market, By Product
7 Human Microbiome Market, By Application
8 Human Microbiome Market, By Disease
9 Human Microbiome Research Spending Market, By Product
10 Human Microbiome Research Spending Market, By Technology
11 Geographic Analysis
12 Competitive Landscape
13 Company Profiles
14 Appendix
- Du Pont De Nemours and Company
- Enterome Bioscience
- Merck & Co., Inc.
- Metabiomics Corporation
- Microbiome Therapeutics, Llc
- Osel, Inc.
- Second Genome, Inc.
- Vedanta Biosciences, Inc.
- Vithera Pharmaceuticals
- Yakult Honsha Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/q8ggs7/human_microbiome
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices


Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
Robinhood Expands Sports Event Contracts With Player Performance Wagers
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing
Shell M&A Chief Exits After BP Takeover Proposal Rejected
OpenAI Explores Massive Funding Round at $750 Billion Valuation
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 



